Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biogen Idec, PDL develop and commercialize three antibodies

Executive Summary

Biogen Idec and Protein Design Labs will jointly develop, manufacture, and commercialize three of PDL's Phase II antibody candidates--M200 (volociximab) and HuZAF (fontolizumab) for all indications, and daclizumab for multiple sclerosis and areas excluding transplant, asthma, and respiratory diseases (indications in which PDL is partnered with Roche under a September 2004 agreement).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies